Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been linked with behavioral side effects.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.